These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer. Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369 [TBL] [Abstract][Full Text] [Related]
4. Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235. Markovina S; Duan F; Snyder BS; Siegel BA; Machtay M; Bradley JD Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):597-605. PubMed ID: 26461002 [TBL] [Abstract][Full Text] [Related]
5. The predictive value of Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034 [TBL] [Abstract][Full Text] [Related]
6. Impact of mediastinal tumor burden and lymphatic spread in locally advanced non-small-cell lung cancer: A secondary analysis of the multicenter randomized PET-Plan trial. Gkika E; Dejonckheere CS; Sahlmann J; Barth SA; Schimek-Jasch T; Adebahr S; Hecht M; Miederer M; Brose A; Binder H; König J; Grosu AL; Nestle U; Rimner A Radiother Oncol; 2024 Nov; 200():110521. PubMed ID: 39236984 [TBL] [Abstract][Full Text] [Related]
7. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL; Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429 [TBL] [Abstract][Full Text] [Related]
8. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial. Fleckenstein J; Hellwig D; Kremp S; Grgic A; Gröschel A; Kirsch CM; Nestle U; Rübe C Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e283-9. PubMed ID: 21470782 [TBL] [Abstract][Full Text] [Related]
9. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival. Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854 [TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy. Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123 [TBL] [Abstract][Full Text] [Related]
11. Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235. Ohri N; Duan F; Machtay M; Gorelick JJ; Snyder BS; Alavi A; Siegel BA; Johnson DW; Bradley JD; DeNittis A; Werner-Wasik M J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25688115 [TBL] [Abstract][Full Text] [Related]
12. Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by Mazzola R; Fiorentino A; Di Paola G; Giaj Levra N; Ricchetti F; Fersino S; Tebano U; Pasetto S; Ruggieri R; Salgarello M; Alongi F J Thorac Oncol; 2017 Mar; 12(3):547-555. PubMed ID: 28126325 [TBL] [Abstract][Full Text] [Related]
13. Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy. van Diessen JN; Chen C; van den Heuvel MM; Belderbos JS; Sonke JJ Radiother Oncol; 2016 Mar; 118(3):447-52. PubMed ID: 26900092 [TBL] [Abstract][Full Text] [Related]
14. Local and regional treatment response by van Diessen JNA; La Fontaine M; van den Heuvel MM; van Werkhoven E; Walraven I; Vogel WV; Belderbos JSA; Sonke JJ Radiother Oncol; 2020 Feb; 143():30-36. PubMed ID: 31767474 [TBL] [Abstract][Full Text] [Related]
15. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer. Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391 [TBL] [Abstract][Full Text] [Related]
16. Early metabolic response on 18F-fluorodeoxyglucose-positron-emission tomography/computed tomography after concurrent chemoradiotherapy for advanced stage III non-small cell lung cancer is correlated with local tumor control and survival. Jeong JU; Chung WK; Nam TK; Song JY; Yoon MS; Kim YC; Kim KS; Oh IJ; Ban HJ; Kwon SY; Bom HS; Ahn SJ Anticancer Res; 2014 May; 34(5):2517-23. PubMed ID: 24778069 [TBL] [Abstract][Full Text] [Related]
17. Pretreatment 18F-FDG PET Textural Features in Locally Advanced Non-Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235. Ohri N; Duan F; Snyder BS; Wei B; Machtay M; Alavi A; Siegel BA; Johnson DW; Bradley JD; DeNittis A; Werner-Wasik M; El Naqa I J Nucl Med; 2016 Jun; 57(6):842-8. PubMed ID: 26912429 [TBL] [Abstract][Full Text] [Related]
18. An investigative expansion of a competing risk model for first failure site in locally advanced non-small cell lung cancer. Lacoppidan T; Vogelius IR; Pøhl M; Strange M; Persson GF; Nygård L Acta Oncol; 2019 Oct; 58(10):1386-1392. PubMed ID: 31271118 [No Abstract] [Full Text] [Related]
19. Prognostic importance of Kanyilmaz G; Benli Yavuz B; Aktan M; Sahin O Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):20-26. PubMed ID: 31668790 [TBL] [Abstract][Full Text] [Related]
20. ¹⁸F-FDG PET-CT during chemo-radiotherapy in patients with non-small cell lung cancer: the early metabolic response correlates with the delivered radiation dose. Massaccesi M; Calcagni ML; Spitilli MG; Cocciolillo F; Pelligrò F; Bonomo L; Valentini V; Giordano A Radiat Oncol; 2012 Jul; 7():106. PubMed ID: 22781363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]